 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || IMMUNA (IMM01-STEM) / Immunis
Trial completion, Trial primary completion date: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - Nov 7, 2024
P1/2, N=13, Completed, Sponsor: Immunis, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Nov 2024 --> Aug 2024
- |||| IMMUNA (IMM01-STEM) / Immunis
New P2 trial: Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness (clinicaltrials.gov) - Sep 20, 2024
P2, N=55, Not yet recruiting, Sponsor: Immunis, Inc.
- | IMMUNA (IMM01-STEM) / Immunis
Enrollment closed, Trial primary completion date: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - Sep 19, 2024
P1/2, N=13, Active, not recruiting, Sponsor: Immunis, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Nov 2024 --> Aug 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2024 --> Nov 2024
- | IMMUNA (IMM01-STEM) / Immunis
Trial primary completion date: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - Mar 5, 2024
P1/2, N=18, Recruiting, Sponsor: Immunis, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2024 --> Nov 2024 Trial primary completion date: Dec 2023 --> Aug 2024
- | IMMUNA (IMM01-STEM) / Immunis
Trial completion date, Trial primary completion date: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - Feb 21, 2023
P1/2, N=18, Recruiting, Sponsor: Immunis, Inc.
Trial primary completion date: Dec 2023 --> Aug 2024 Trial completion date: May 2023 --> Sep 2024 | Trial primary completion date: Feb 2023 --> Dec 2023
- || IMMUNA (IMM01-STEM) / Immunis
Enrollment open: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - Sep 21, 2022
P1/2, N=18, Recruiting, Sponsor: Immunis, Inc.
Trial completion date: May 2023 --> Sep 2024 | Trial primary completion date: Feb 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- | IMMUNA (IMM01-STEM) / Immunis
Trial completion date, Trial initiation date, Trial primary completion date: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - May 23, 2022
P1/2, N=18, Not yet recruiting, Sponsor: Immunis, Inc.
Not yet recruiting --> Recruiting Trial completion date: Jun 2022 --> Apr 2023 | Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Jan 2023
- | IMMUNA (IMM01-STEM) / Immunis
New P1/2 trial: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov) - Jan 27, 2022
P1/2, N=18, Not yet recruiting, Sponsor: Immunis, Inc.